Pretreatment with TNF inhibitors may improve outcomes of combination cancer immunotherapy

This study proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy in animal models. This clinical strategy consists of blocking TNF protein while applying combination immunotherapy treatment (inhibition therapy of PD-1 and CTLA-4, other proteins that ‘slow down’ the immune response).

About admin

Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge. Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →

Leave a Reply

Your email address will not be published. Required fields are marked *